John Moroney to Dasatinib
This is a "connection" page, showing publications John Moroney has written about Dasatinib.
Connection Strength
0.058
-
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. Gynecol Oncol. 2023 09; 176:16-24.
Score: 0.058